Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 11:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 39 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Estradiol Vaginal Cream Clear all

Conditions: Pelvic Floor Disorders
Interventions: Postmenopausal, topical vaginal estrogen cream, Placebo Comparator: Postmenopausal, topical placebo cream; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Overactive Bladder Syndrome
Interventions: Vaginal estrogen, Mirabegron 50 MG [Myrbetriq]; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Estrogen, Menopause, Pelvic Floor Disorders, Surgery
Interventions: Premarin, Vagifem; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 90 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Post-menopause, Pre-menopause, Sexual Function, Menopause, Vaginal Dryness, Painful Intercourse
Interventions: DHEA ovals, Estradiol 0.01% Vag Cream; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 40 Years to 90 Years · Female only
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Postoperative Bleeding, Gender Dysphoria, Hysterectomy
Interventions: Use of topical estradiol, No intervention; Drug · Other
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Obstetric; Injury Pelvic Floor, Sexual Dysfunction, Anal Incontinence, Urinary Incontinence
Interventions: Estradiol 0.01% Vag Cream, Placebo vaginal cream; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Overactive Bladder
Interventions: Toviaz, Premarin, Placebo cream; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 30 Years to 100 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Atrophic Vaginitis
Interventions: Premarin® Vaginal Cream, Premarin® oral tablets; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 2
States / cities: Miami, Florida • Baltimore, Maryland

Conditions: Prepubertal Labial Adhesions
Interventions: Estradiol cream 0.01%, Cetaphil; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 3 Months to 12 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Vulvovaginal Atrophy
Interventions: WC3011 Estradiol Vaginal Cream, Vehicle; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 57
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 48 more

Conditions: Atrophic Vaginitis
Interventions: Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream, Placebo Vaginal Cream; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 21
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Vulvar and Vaginal Atrophy
Interventions: Estrace® Cream, Estradiol Vaginal Cream, Vehicle Cream; Drug
Lead sponsor: Prasco LLC; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 27
States / cities: Sacramento, California • San Diego, California • Denver, Colorado + 23 more

Conditions: Atrophy of Vagina, Vaginal Ulceration, Vaginitis
Interventions: Estradiol, placebo; Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: HIV Prevention
Interventions: TFV 1% gel, Estradiol vaginal cream; Drug
Lead sponsor: CONRAD; Other
Eligibility: 21 Years to 89 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Pelvic Organ Prolapse, Menopause
Interventions: Premarin, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery

VEDA Study (DHEA vs Estradiol)

Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy

Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery

Premarin Versus Toviaz for Treatment of Overactive Bladder

Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis

Treatment of Prepubertal Labial Adhesions

Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia

A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis

Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy

Vaginal Creams to Reduce Vaginal Erosion in Pessary Users

Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity

Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor